{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-009115","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.566531+00:00","generated_at":"2026-05-15T12:55:45.935465+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Gyre Therapeutics projects $400-600M in F351 revenue within 5 years; provides Cullgen TRK degrader update","bullets":["Company sees potential $400-600M revenue for Hydronidone (F351) in liver fibrosis within 5 years.","Expects ETUARY for lung fibrosis to sustain ~$100M absent near-term generic competition.","Sees 20-25% net margins for commercial products; favorable R&D tax deductibility in Beijing/Shanghai campuses.","Cullgen's TRK degrader CG001419 Phase 2 pain trial enrolling at doses expected to show ~95% TRK degradation.","Cullgen's degrader antibody conjugates (DAC) show ~10-100x potency vs standalone degrader in vitro/animal models."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-009115","json":"https://secwatch.observer/filing/0001140361-26-009115.json","markdown":"https://secwatch.observer/filing/0001140361-26-009115.md","text":"https://secwatch.observer/filing/0001140361-26-009115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126009115/0001140361-26-009115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126009115/ef20067723_form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:55:45.935465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}